Evolution Wealth Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,864
Closed -$212K 148
2024
Q3
$212K Sell
1,864
-29
-2% -$3.44K 0.04% 126
2024
Q2
$237K Sell
1,893
-161
-8% -$20.7K 0.05% 122
2024
Q1
$271K Sell
2,054
-122
-6% -$15K 0.05% 110
2023
Q4
$237K Buy
2,176
+40
+2% +$4.15K 0.05% 110
2023
Q3
$220K Buy
2,136
+7
+0.3% +$754 0.05% 105
2023
Q2
$246K Sell
2,129
-33
-2% -$3.75K 0.05% 100
2023
Q1
$230K Buy
2,162
+347
+19% +$37.5K 0.06% 107
2022
Q4
$201K Buy
+1,815
New +$186K 0.05% 118
2022
Q1
Sell
-2,786
Closed -$214 137
2021
Q4
$214 Buy
2,786
+262
+10% +$20.9K 0.03% 127
2021
Q3
$190K Buy
2,524
+341
+16% +$25.9K 0.04% 117
2021
Q2
$170K Sell
2,183
-222
-9% -$16.5K 0.03% 131
2021
Q1
$177K Buy
2,405
+618
+35% +$45.6K 0.04% 113
2020
Q4
$139K Sell
1,787
-693
-28% -$53K 0.03% 118
2020
Q3
$196K Buy
2,480
+443
+22% +$34.7K 0.05% 97
2020
Q2
$150K Buy
2,037
+766
+60% +$57.7K 0.05% 95
2020
Q1
$94K Sell
1,271
-436
-26% -$34.3K 0.04% 90
2019
Q4
$148K Buy
1,707
+1,397
+451% +$115K 0.04% 88
2019
Q3
$25K Sell
310
-1,017
-77% -$81.5K 0.01% 77
2019
Q2
$106K Buy
+1,327
New +$102K 0.05% 61

Other funds holding MRK

Evolution Wealth Advisors's MRK Position: Q4 2024 in Review

Evolution Wealth Advisors sold out of Merck (MRK) in Q4 2024, closing a stake of 1,864 shares — an estimated $212K sold.

Evolution Wealth Advisors first reported a position in MRK in Q2 2019 and held it in 19 quarters. The position peaked at $271K in Q1 2024. 3,607 funds tracked by Wall St. Rank hold MRK as of Q4 2024.

  • Evolution Wealth Advisors reported no remaining Merck position as of Q4 2024 after selling out during the quarter.
  • Evolution Wealth Advisors sold 1,864 Merck shares in Q4 2024, an estimated $212K.
  • Evolution Wealth Advisors first reported a position in Merck in Q2 2019 and held it in 19 quarters.
  • Evolution Wealth Advisors's Merck position peaked at $271K in Q1 2024.
  • 3,607 funds tracked by Wall St. Rank held Merck as of Q4 2024.

Based on Evolution Wealth Advisors's 13F filing for Q4 2024, filed 17 Jan 2025.